Allogeneic hematopoietic cell transplantation provides a curative treatment modality for aggressive hematological malignancies primarily through the graft-versus-leukemia effect. However, malignant clones frequently develop diverse immune evasion mechanisms that undermine donor alloreactivity. Recent multicenter genomic analyses highlight chromosome 6 deletion as a critical cytogenetic lesion that impairs post-transplant outcomes. Because the short arm of chromosome 6 harbors the human leukocyte antigen genomic complex, its structural loss significantly disrupts immune surveillance. Consequently, clinicians must evaluate these cytogenetic alterations during pre-transplant risk assessment to improve therapeutic decisions.

Biological Significance of Chromosome 6 Deletion in Hematology

The short arm of chromosome six, designated as 6p, contains the major histocompatibility complex locus encoding human leukocyte antigen molecules. These surface glycoproteins present tumor antigens directly to donor-derived CD8+ cytotoxic T lymphocytes and natural killer cells. When malignant clones acquire a chromosome 6 deletion, they frequently lose critical human leukocyte antigen alleles. Consequently, the donor immune system fails to recognize residual leukemic blasts, directly blunting the potent graft-versus-leukemia response. In addition, structural aberrations on chromosome six frequently co-occur with complex karyotypes, including TP53 mutations. Therefore, malignant cells gain dual advantages: intrinsic proliferative resilience and acquired extrinsic immune resistance. Researchers historically identified acquired genomic deletions of 6p during post-transplant relapse, particularly following haploidentical transplantation. However, recent evidence confirms that primary baseline deletions present at diagnosis trigger identical immune escape mechanisms. Clinicians previously overlooked these baseline microdeletions because conventional metaphase cytogenetics lacked resolution. Today, advanced molecular karyotyping reveals that pre-existing alterations compromise transplant efficacy far earlier than previously anticipated.

Clinical Registry Findings on Relapse and Survival Rates

Recent registry databases provide compelling real-world evidence regarding the prognostic gravity of these cytogenetic defects. Specifically, investigators analyzed thousands of patients with acute myeloid leukemia and myelodysplastic syndromes undergoing allogeneic cell transplantation. Patients harboring the deletion demonstrated an alarmingly elevated cumulative incidence of disease recurrence compared to unaffected cohorts. In univariate analyses, individuals with the deletion showed a two-year relapse rate of nearly fifty percent, whereas patients lacking the lesion experienced half that frequency. Furthermore, multivariate models confirmed that the deletion represents an independent adverse prognostic factor for overall survival. The increased relapse rate occurred across diverse conditioning regimens, donor types, and graft sources. Interestingly, transplant-related mortality did not significantly differ between cohorts, confirming that disease recurrence drove inferior survival. Moreover, patients carrying concurrent adverse cytogenetic lesions faced even steeper survival penalties, emphasizing synergistic multi-hit genomic instability. These registry findings demonstrate that baseline cytogenetic loss of chromosome six dictates post-transplant relapse kinetics far more aggressively than standard calculators predict.

Mechanisms Driving Immune Evasion and Alloreactive Failure

The graft-versus-leukemia reaction relies heavily on donor T-cell receptor engagement with foreign or mismatched HLA molecules. When leukemic stem cells lose these presentation platforms via genomic loss, donor effector cells become functionally blind. Furthermore, loss of HLA expression disrupts the delicate balance governing natural killer cell alloreactivity. Natural killer cells utilize killer cell immunoglobulin-like receptors to sample recipient HLA ligands, initiating targeted cytolysis when inhibitory signals diminish. However, complete genomic loss can dysregulate these signaling pathways, blunting natural killer surveillance. In addition, tumors harboring these deletions frequently upregulate alternative checkpoint molecules within the immunosuppressive marrow microenvironment. Consequently, donor cytotoxic cells rapidly encounter exhaustion markers, including PD-1 and TIM-3, which further paralyzes effector function. Because leukemic blasts maintain high proliferative capacity without immune restriction, microscopic residual disease expands rapidly into frank clinical relapse. Understanding these multifaceted evasive maneuvers underscores why standard post-transplant donor lymphocyte infusions often fail to rescue patients experiencing relapse.

Optimizing Diagnostic Screening and Risk Stratification Protocols

Given the profound prognostic implications of this genomic lesion, clinicians must refine diagnostic workflows prior to transplant conditioning. Standard G-banded karyotyping exhibits variable sensitivity for subtle subclonal deletions or copy-neutral loss of heterozygosity. Therefore, comprehensive diagnostic protocols should incorporate chromosomal microarray analysis or next-generation sequencing alongside traditional cytogenetics. Identifying microdeletions or uniparental disomy of chromosome 6p allows transplant physicians to recalibrate baseline prognostic scores before donor selection. In addition, clinicians must screen for co-occurring mutations in genes regulating DNA damage responses. When molecular testing detects these deletions early, multidisciplinary transplant boards can design tailored conditioning strategies rather than relying on standard protocols. For example, clinicians might reconsider the intensity of myeloablative conditioning or explore targeted induction regimens to minimize measurable residual disease before graft infusion. Furthermore, post-transplant monitoring must intensify for these high-risk candidates. Incorporating frequent molecular assays for residual disease ensures clinicians detect early kinetics before overt morphologic recurrence develops.

Emerging Therapeutic Strategies to Overcome Immune Resistance

Overcoming the immunologic barriers imposed by structural chromosome abnormalities requires innovative cellular and pharmacological interventions. Because conventional alloreactive donor lymphocytes depend on intact HLA presentation, unmanipulated donor lymphocyte infusions offer minimal clinical utility against HLA-deficient blasts. Instead, oncologists are investigating HLA-independent cellular therapies to circumvent presentation loss. Specifically, chimeric antigen receptor T-cell therapies and bispecific T-cell engagers target surface differentiation markers such as CD33 or CD123 without relying on HLA molecules. Moreover, natural killer cell adoptive therapies engineered with activating chimeric receptors demonstrate considerable promise in targeting HLA-negative leukemic populations. Pharmacological approaches also offer potential synergy by modulating the marrow tumor microenvironment. For example, hypomethylating agents combined with targeted small-molecule inhibitors can enhance blast immunogenicity and suppress regulatory T-cell expansion. In addition, novel epigenetic modifiers may restore surface expression of antigen-processing machinery. By integrating HLA-independent immunotherapies with proactive maintenance regimens, transplant teams can significantly improve survival outcomes for this historically vulnerable population.

Frequently Asked Questions

How does chromosome 6 deletion cause leukemia relapse after transplantation?

A chromosome 6 deletion disrupts the genetic locus housing human leukocyte antigen genes. Because donor T lymphocytes rely on these surface molecules to identify leukemic blasts, losing them prevents alloreactive immune recognition. Consequently, the donor graft cannot execute an effective graft-versus-leukemia response. Without functional immune surveillance, residual leukemic cells proliferate rapidly within the marrow. This genomic escape mechanism directly promotes therapy-resistant disease recurrence after allogeneic transplantation.

Can conventional karyotyping detect all chromosome 6 deletions reliably?

Conventional G-banded karyotyping identifies large structural deletions on chromosome 6, but it frequently misses smaller subclonal microdeletions or copy-neutral loss of heterozygosity. Therefore, comprehensive diagnostic workups require higher-resolution molecular platforms such as chromosomal microarray analysis or targeted next-generation sequencing. Utilizing these advanced assays ensures accurate identification of HLA genomic loss before transplant conditioning. Early molecular detection allows clinicians to stratify patient risk accurately and personalize conditioning protocols accordingly.

What treatments are effective for leukemia relapsing with HLA loss?

Standard donor lymphocyte infusions usually fail against HLA-deficient relapses because infused T cells cannot recognize the leukemic targets. Instead, clinicians must deploy HLA-independent modalities to achieve remissions. Chimeric antigen receptor T cells and bispecific antibodies target specific lineage surface markers directly without requiring HLA presentation. In addition, adoptive natural killer cell therapies and hypomethylating epigenetic agents offer promising alternatives by restoring alternative anti-tumor responses and overcoming severe immune evasion barriers.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Tamaki M et al. Adverse impact of deletion of the chromosome 6 on clinical outcomes after allogeneic hematopoietic transplantation. Blood Adv. 2026 Oct 23. doi: undefined. PMID: 42913459.
2. Pagliuca S, Gurnari C, Zhang K, et al. Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation. Nat Commun. 2023;14(1):3778.
3. Christopher MJ, Petti AA, Rettig MP, et al. Immune escape of leukemia following allogeneic transplantation. N Engl J Med. 2018;379(24):2330-2341.